Patients with conditions showing strong preclinical evidence and limited alternative treatment options may represent reasonable candidates following thorough informed consent discussions
There were no differences in age, BMI, gender, HDRS-24 scores before treatment, treatment days and other demographic characteristics between the effective-treatment and ineffective-treatment groups, there was significant difference in the reduction rate of HDRS-24 scores and HDRS-24 scores after treatment between the two groups (Table 2)
This review provides a meticulous exploration of GLP-1, elucidating its origin, secretion, and the challenges associated with its clinical application due to its fragility in the presence of DPP-IV, resulting in a short half-life
It has been studied for decades for its role in skin and regeneration
BPC-157 Protocol (2 mL Reconstitution = 2.5 mg/mL) Route: Subcutaneous injection, preferably near the site of injury